CJC/IPA Protocol (CJC-1295/Ipamorelin)

GHRH/GHRP Combination · Growth Hormone Optimization

Overview

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.

CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.

Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.

Sustained GH patterns may accelerate muscle repair between exercise sessions.

GH optimization helps maintain muscle during caloric restriction or aging.

Growth hormone promotes lipolysis while supporting lean tissue maintenance.

Mechanism

Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.

Research areas

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.
Sustained GH patterns may accelerate muscle repair between exercise sessions.
GH optimization helps maintain muscle during caloric restriction or aging.
Growth hormone promotes lipolysis while supporting lean tissue maintenance.
Enhanced GH patterns may improve glucose and fat utilization.
Evening GH peaks align with deeper, more restorative sleep patterns.
Sustained GH elevation supports skin elasticity and connective tissue health.
Growth hormone supports tissue repair and recovery from exercise or injury.
Enhanced collagen synthesis supports joint and connective tissue integrity.

Research notes

Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Persistent joint pain or swelling indicating fluid retention
Significant blood glucose changes or diabetic control issues
Unusual fatigue, lethargy, or mood deterioration
Injection site infections or persistent reactions
Numbness or tingling in hands/feet
Signs of accelerated tumor growth if cancer history exists
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders

References

FAQs

Why do people combine CJC-1295 and Ipamorelin instead of using them separately?

CJC-1295 and Ipamorelin target GH secretion through complementary mechanisms—CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin receptors—creating synergistic effects greater than either peptide alone. Ipamorelin uniquely avoids cortisol elevation, making the combination particularly effective and tolerable.

Can I use the CJC/IPA protocol if I have a history of diabetes?

CJC/IPA combinations require caution with diabetes history due to GH's insulin-antagonistic effects. Both peptides elevate growth hormone which can impair glucose tolerance. Medical supervision and regular blood glucose monitoring are essential before starting, especially with the continuous GH elevation this protocol provides.

What's the advantage of Ipamorelin over GHRP-6 in this combination?

Ipamorelin is selective for GH release and does NOT elevate cortisol or prolactin even at high doses, whereas GHRP-6 causes significant appetite stimulation and potential cortisol elevation. For the CJC/IPA protocol, Ipamorelin provides cleaner GH stimulation without the side effects of broader GHRP peptides.

Should CJC/IPA be dosed together in the same injection or separately?

Both approaches work—some use blended vials containing both peptides at a 1:1 ratio, while others inject separately at the same or different sites. Blended vials offer convenience but allow less flexibility to adjust individual peptide doses, while separate vials let you customize ratios if needed.